Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EULAMDIMA

Financiado

Cerrado

Joint European and Latin American Research Network on Diabetic Microangiopathy

The WHO estimates that the metabolic disease diabetes will become the leading cause of morbidity and premature mortality by the year 2020, severely affecting both developed and developing countries. Diabetic microvascular complica... ver más

31/10/2016

UNIVERSITAIR MEDIS...

452K€

Presupuesto del proyecto: 452K€

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITAIR MEDISCH CENTRUM...

0.00€ | Lider

UHEI

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SUMMIT SUrrogate markers for vascular Micro and Macrovascular hard... 35M€ Cerrado

SUMMIT SUrrogate markers for vascular Micro- and Macrovascular hard... 35M€ Cerrado

Hypo-RESOLVE Hypoglycaemia REdefining SOLutions for better liVEs 27M€ Cerrado

EUIN2013-51220 EUROPEAN CONSORTIUM FOR RISK STRATIFICATION AND MANAGEMENT O... 23K€ Cerrado

METAFORA Miniaturised Metabolomics Platform for Microvascular Researc... 178K€ Cerrado

ICEBERG Discovery of Type 2 Diabetes Targets 3M€ Cerrado

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 452K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The WHO estimates that the metabolic disease diabetes will become the leading cause of morbidity and premature mortality by the year 2020, severely affecting both developed and developing countries. Diabetic microvascular complications affect eyes, kidneys, and nerves. Hyperglycaemia is the most important risk factor for diabetic microangiopathy. However, the mechanisms by which poor glucose control mediates functional and structural changes are poorly understood. New insight into the key pathogenic pathways is crucial for novel therapeutic strategies to prevent and cure these diabetes-associated microvascular complications. EULAMDIMA builds on a novel and unique international focus on microvascular mechanisms as outlined in the FP-7 programme DIAMAP. It has a multidisciplinary and translational approach combining state-of-the-art platforms of (pre-)clinical expertise with expertise in vascular or neuronal biology, novel model systems, and endothelial targeted therapeutic strategies. It fosters the exchange of knowledge by making use of international complementary expertise and provides access to fundamental genetic and environmental data. The present scheme contributes to the construction of new and the enhancement of existing networks. It builds on the UMCG-UHEI cooperation established within the International Research Training Group GRK880 Vascular Medicine as well as the cooperation between UMCG and the Latin American partners UNAM and UNAB within the Abel Tasman Talent Programme. EULAMDIMA ultimately aims to define novel targets for the treatment of microvascular complications related to diabetes to help alleviate the immense burden that is posed on both individuals and societies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores